Meet the team that is driving our mission to discover insights that cure disease and heal healthcare
Colin Hill is a leading voice in healthcare technology and precision medicine and brings impressive leadership experience in commercializing machine learning technologies in the biopharmaceutical and managed care industries. He co-founded GNS Healthcare, a leading AI-driven precision medicine company, in 2000 and has since served as Chairman & CEO. In 2020 the company launched the in silico patient, a highly accurate computer model of disease.
Colin sits on board of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company, and PPD, a leading global contract research organization. He is also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council.
Colin was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014). He was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.
He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.
He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.
VP Precision Medicine
Jeanne Latourelle heads the Precision Medicine team at GNS. Prior to GNS in 2015, Jeanne was at the Boston University School of Medicine where she gained over 10 years of experience in NIH-funded academic research, specifically in the field of genetic epidemiology. Her areas of research included statistical genetics of complex disease, with a focus on neurodegenerative disease and pulmonary function. She has co-authored over 40 papers, including high impact publications in Nature, the New England Journal of Medicine, the Journal of the American Medical Association and Lancet Neurology.
Jeanne holds a BS in biomedical engineering from Boston University, a MS in Mechanical Engineering from MIT and a DSc of Epidemiology from Boston University School of Public Health.
SVP Business Development
Keith leads GNS’ business development team and is responsible for client initiatives within the pharmaceutical industry and his primary responsibilities focus on client relationships and communication of needs. Working to understand customer needs and challenges Keith ensures that the GNS teams provide solutions to support decisions making through discovery, development, and commercialization. Keith has experience in Business Development for over 17 years and in the pharmaceutical industry for 28 years. Prior to joining GNS, he worked at several technology companies focused on bringing innovative capabilities to the discovery and development of human therapeutics such as in-silico fragment based drug design and gene evolution protein engineering. He also spent the first 10 years at Merck & Co and EMD where he learned the pharmaceutical development process and managed several products from discovery through to product approval and launch. This experience has provided him with a broad level of experience and understanding of the challenges faced in the global healthcare and pharmaceutical markets today.
EVP of Market Access and Payer
Prior to GNS, Dr. Steinberg was co-founder and CEO of xG Health Solutions, a company formed by Geisinger Health System and backed by Oak Investment Partners that worked with more than 80 health care delivery systems to improve their clinical and financial performance. From 2011 to 2015, Dr. Steinberg was Executive Vice President of Innovation and Dissemination and Chief, Healthcare Solutions Enterprise at Geisinger. Prior to joining Geisinger, Dr. Steinberg, was SVP for Clinical Strategy, Quality & Outcomes at WellPoint, Inc. (now Anthem) and President and CEO of Resolution Health Inc. (RHI), a health care claims data analytics and intervention company acquired by WellPoint that provided innovative quality improvement and cost reduction services to health plans, employers, PBMs and disease management companies.Prior to founding RHI, Dr. Steinberg spent six years as VP of Covance Health Economics and Outcomes Services Inc. . While at Covance, Dr. Steinberg led the teams that developed three HEDIS measures and helped produce a set of measures that are used to measure quality of care in all dialysis units in the U.S.
Dr. Steinberg is an Adjunct Professor of Medicine and of Health Policy and Management at Johns Hopkins University, as well as a member of the Health Care Management Advisory Board of the Johns Hopkins Carey Business School. He spent over 12 years at Johns Hopkins University as a full time Professor of Medicine and Health Policy and Management. Dr. Steinberg received an A.B. degree from Harvard College (Summa Cum Laude), an M.D. from Harvard Medical School and a Master of Public Policy degree from Harvard’s Kennedy School of Government. His residency training in internal medicine was performed at the Massachusetts General Hospital.
Mark Pottle is responsible for the finance, accounting and legal functions of GNS Healthcare.
Before joining GNS Healthcare, Mark was CFO of N-of-One Therapeutics, which provides analysis and interpretation of a tumor’s genome so that providers can personalize cancer treatments for patients. Prior to N-of-One, Mark worked at Picis Inc., which provides EMRs for emergency departments, ICUs, and ORs. After Picis was sold to United Healthcare/Optum in 2010, Mark became the CFO of Optum’s Accountable Care Organization division. Mark has also previously worked at several start-up to mid-level companies and has helped raise over $50 million of venture-backed funding, as well as over $150 million in private equity funding.
Mark is also a veteran of the U.S. Army. He graduated from University of New Hampshire with a degree in economics and holds an MBA from Southern New Hampshire University.
VP People and Culture
Ken is responsible for the Human Resource function of GNS Healthcare.
Before joining GNS Healthcare, Ken was the Vice President of Human Resources for ORIG3N Inc, a Biotechnology company that specializes in DNA testing and regenerative medicine. Prior to ORIG3N Ken was the VP of HR for Skyword Inc., a company that developed proprietary software to enhance Content Marketing for its customers. He has worked at multiple start-up companies including CambridgeSoft that created an electronic notebook (ELN) for the Pharma Industry. Ken was part of the senior team that merged CambridgeSoft and 2 other companies into the PerkinElmer Informatics group where he led the HR function for the $150 million-dollar division. Ken has consulted to multiple software, biotech and technology companies over the years and was the VP of HR for an incubator that launched software security companies.
Ken graduated Bridgewater State University with a BS in Education.
Chief Oncology Advisor
Ravi B. Parikh, MD, MPP, FACP, is an Assistant Professor in the Department of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania and Staff Physician at the Corporal Michael J. Crescenz VA Medical Center. Dr. Parikh is a practicing medical oncologist with expertise in delivery system reform and informatics. His work has focused on three core areas: (1) the use of health technology to improve routine patient care; (2) quality of life and survivorship care in oncology; and (3) payment reform for advanced illnesses.
Dr. Parikh's work on medical technology and advanced illness in leading academic journals including Science, The New England Journal of Medicine, and JAMA. He is Senior Clinical Advisor and Board Member at the Coalition to Transform Advanced Care (C-TAC) and was elected to the National Council of Resident/Fellow Members of the American College of Physicians.
Dr. Parikh is a graduate of Harvard Medical School, Harvard College, and the John F. Kennedy School of Government. He completed a residency in internal medicine at Brigham and Women's Hospital and a fellowship in Hematology and Oncology at the University of Pennsylvania. He has received the National Palliative Care Research Center Kornfeld Scholars Award, Conquer Cancer Foundation Young Investigator Award, the American College of Physicians Joseph E. Johnson Leadership Award, and the AMA Foundation Excellence in Medicine Leadership Award.